PepGen Inc. financial data

Symbol
PEPG on Nasdaq
Industry
Pharmaceutical Preparations
Location
1 Marina Park Drive, Suite 900, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 910 % +18.4%
Debt-to-equity 22.3 % -15.4%
Return On Equity -61 % -5.96%
Return On Assets -49.9 % -9.51%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.7M shares +1.04%
Common Stock, Shares, Outstanding 32.6M shares +36.9%
Entity Public Float 273M USD +179%
Common Stock, Value, Issued 3K USD +50%
Weighted Average Number of Shares Outstanding, Basic 31.6M shares +32.7%
Weighted Average Number of Shares Outstanding, Diluted 31.6M shares +32.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 76.5M USD +12.3%
General and Administrative Expense 21.3M USD +27.8%
Operating Income (Loss) -97.7M USD -15.3%
Nonoperating Income (Expense) 7.14M USD +14.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -90.6M USD -15.3%
Net Income (Loss) Attributable to Parent -90M USD -14.4%
Earnings Per Share, Basic -2.85 USD/shares +13.6%
Earnings Per Share, Diluted -2.85 USD/shares +13.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 49.4M USD -38.8%
Marketable Securities, Current 70.8M USD +139%
Cash, Cash Equivalents, and Short-term Investments 120M USD +8.88%
Assets, Current 124M USD +9.84%
Property, Plant and Equipment, Net 3.72M USD -22%
Operating Lease, Right-of-Use Asset 21.4M USD -9.26%
Other Assets, Noncurrent 426K USD -3.62%
Assets 151M USD +5.47%
Accounts Payable, Current 1.75M USD +74.3%
Employee-related Liabilities, Current 3.62M USD +52.7%
Accrued Liabilities, Current 11.9M USD -12.4%
Liabilities, Current 16.7M USD -4.76%
Operating Lease, Liability, Noncurrent 15.6M USD -8.97%
Liabilities 32.3M USD -6.84%
Accumulated Other Comprehensive Income (Loss), Net of Tax 23K USD -32.4%
Retained Earnings (Accumulated Deficit) -271M USD -49.6%
Stockholders' Equity Attributable to Parent 119M USD +9.41%
Liabilities and Equity 151M USD +5.47%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.5M USD -46.1%
Net Cash Provided by (Used in) Financing Activities 87M USD
Net Cash Provided by (Used in) Investing Activities -11.3M USD -856%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 32.6M shares +36.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 53.1M USD
Deferred Tax Assets, Valuation Allowance 76.8M USD +53.1%
Deferred Tax Assets, Gross 83.9M USD +44.5%
Operating Lease, Liability 18.7M USD -7.18%
Depreciation 376K USD +151%
Payments to Acquire Property, Plant, and Equipment 53K USD -95.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -90M USD -14.6%
Lessee, Operating Lease, Liability, to be Paid 25M USD -10.7%
Property, Plant and Equipment, Gross 6.76M USD +6.72%
Operating Lease, Liability, Current 3.09M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.19M USD +3.01%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.09M USD +3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.36M USD -19.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.28M USD +2.98%
Deferred Tax Assets, Operating Loss Carryforwards 17M USD +112%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.38M USD +3.02%
Depreciation, Depletion and Amortization 1.5M USD +25%
Deferred Tax Assets, Net of Valuation Allowance 76.8M USD +53.1%
Share-based Payment Arrangement, Expense 11.5M USD +62.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%